Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

36.94 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Tech Stocks Edge Up, AMD Rallies 5%, 30-Year Yields Eye Danger Zone: What's Driving Markets Wednesday?
Nasdaq 100 rises further as Nvidia and AMD rally on Middle East investment hopes, while gold tumbles and Treasury yields surge. 
Via Benzinga
Why Exelixis Stock Is Skyrocketing Today
Via The Motley Fool
Exelixis Crushes Q1 Earnings Estimates With Strong Cabometyx Sales, Raises 2025 Revenue Guidance
Exelixis beats Q1 estimates with strong Cabometyx sales, raises 2025 guidance, and begins Phase 1 trial of its novel NK cell engager, XB628. 
Via Benzinga
Biotech Leader Exelixis Pops After Obliterating First-Quarter Profit Expectations
The top-notch biotech company easily beat first-quarter profit expectations. 
Via Investor's Business Daily
Topics Stocks
Exploring Exelixis's Earnings Expectations
 
Via Benzinga
Is the Market Bullish or Bearish on Exelixis?
 
Via Benzinga
Why EXELIXIS INC (NASDAQ:EXEL) qualifies as a high growth stock.
A fundamental and technical analysis of (NASDAQ:EXEL): EXELIXIS INC (NASDAQ:EXEL) may be suited for high growth investing, we'll explore why in this article. 
Via Chartmill
Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
From Exelixis, Inc.
Via Business Wire
EXELIXIS INC (NASDAQ:EXEL) – A Strong Minervini Trend Template Candidate
EXELIXIS INC (NASDAQ:EXEL) – A Strong Minervini Trend Template Candidate 
Via Chartmill
Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025
From Exelixis, Inc.
Via Business Wire
Peering Into Exelixis's Recent Short Interest
 
Via Benzinga
Earnings Scheduled For May 13, 2025
 
Via Benzinga
For those who appreciate growth without the sticker shock, EXELIXIS INC (NASDAQ:EXEL) is worth considering.
Discover EXELIXIS INC, an undervalued growth gem. NASDAQ:EXEL is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing... 
Via Chartmill
Does EXELIXIS INC (NASDAQ:EXEL) align with Mark Minervini’s trading strategy?
A fundamental and technical analysis of (NASDAQ:EXEL): Why EXELIXIS INC (NASDAQ:EXEL) qualifies as a high growth stock. 
Via Chartmill
Expert Outlook: Exelixis Through The Eyes Of 19 Analysts
 
Via Benzinga
Why EXELIXIS INC (NASDAQ:EXEL) is Poised for High Growth.
Exploring high growth characteristics of EXELIXIS INC (NASDAQ:EXEL). A fundamental and technical analysis of (NASDAQ:EXEL). 
Via Chartmill
EXELIXIS INC (NASDAQ:EXEL) qualifies as a high growth stock and is consolidating.
Based on a technical and fundamental analysis of NASDAQ:EXEL we can say: EXELIXIS INC (NASDAQ:EXEL), a strong growth stock, setting up for a breakout. 
Via Chartmill
For those who appreciate growth without the sticker shock, EXELIXIS INC (NASDAQ:EXEL) is worth considering.
EXELIXIS INC was identified as a growth stock that isn't overvalued. NASDAQ:EXEL is excelling in various growth indicators while maintaining a solid financial footing. 
Via Chartmill
EXELIXIS INC (NASDAQ:EXEL) stands out as a stock that provides good value for the fundamentals it showcases.
EXELIXIS INC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:EXEL showcases decent financial health and profitability, coupled with an attractive price. 
Via Chartmill
The Smartest Biotech Stocks to Buy With $50
Via The Motley Fool
FDA Approves Exelixis' Lead Cancer Drug Cabometyx For Expanded Use In Neuroendocrine Tumors
Exelixis' Cabometyx gains FDA approval for advanced neuroendocrine tumors, while phase 3 data confirms sustained survival benefits in renal cancer. 
Via Benzinga
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
From Exelixis, Inc.
Via Business Wire
Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025
From Exelixis, Inc.
Via Business Wire
Looking Into Exelixis's Recent Short Interest
 
Via Benzinga
EXELIXIS INC (NASDAQ:EXEL)—A High-Growth Stock Gearing Up for Its Next Upward Move.
Based on a technical and fundamental analysis of NASDAQ:EXEL we conclude: EXELIXIS INC (NASDAQ:EXEL)—A High-Growth Stock Gearing Up for Its Next Upward Move. 
Via Chartmill
What 25 Analyst Ratings Have To Say About Exelixis
 
Via Benzinga
Don't overlook EXELIXIS INC (NASDAQ:EXEL)—a stock with solid growth prospects and a reasonable valuation.
Discover EXELIXIS INC, an undervalued growth gem. NASDAQ:EXEL is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing... 
Via Chartmill
Is This The Beginning? Insights On Bearish Distribution Patterns
Discover the characteristics of a bearish distribution and the criteria the S&P 500 needs for a technical rally. 
Via Talk Markets
Topics Stocks Stocks / Equities
Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March
From Exelixis, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.